TORONTO, Sept. 21 /PRNewswire/ — According to Millennium
Research Group (MRG), the global authority on medical technology
market intelligence, the introduction and adoption of new growth
factors, combined with greater variety and improved features of
newer products, will drive the US bone graft substitute market to
nearly $2.3 billion through 2015.
Medtronic Spinal & Biologics’ new bone morphogenetic
protein, AMPLIFY, is set to be released in the US market in
2011. Unlike INFUSE, however, AMPLIFY is
combined with a collagen and ceramic matrix designed for
implantation in single-level posterolateral lumbar fusions—an
indication that current bone morphogenetic proteins do not have
approval for. BioMimetic Therapeutics’ Augment Bone Graft is
also set to enter the US market in 2011. The device’s
platelet-derived growth factor is touted by BioMimetic Therapeutics
for having five times the rate of chemotaxis (the ability to
recruit stem cells) and the ability to stimulate the replication of
osteoblasts, not normally typical of bone morphogenetic
proteins.
Orthopedic stem cell products, such as NuVasive’s Osteocel
Plus, Orthofix’s Trinity Evolution, or AlloSource’s
AlloStem, contain stem cells that can differentiate into a
variety of tissue cells to promote bone healing. Such products
offer superior effectiveness compared with many alternative
substitutes. Second-generation synthetic products, such as
Orthovita’s Vitoss BA and Baxter’s Actifuse have
integrated bioactive components that increase osteoinductivity and
thus accelerate bone growth and healing. The improved features of
these products will promote surgeon adoption of these materials
over autografts, while their higher prices compared to older
generation products will contribute to revenue growth over the next
five years.
“Surgeons certainly have a plethora of choice when it comes to
bone graft substitut
‘/>”/>
